化工社化工社 化学情報印刷レポート · 研究参考用
ツボクラリン
(+)-7',12'-ジヒドロキシ-6,6'-ジメトキシ-2,2',2'-トリメチルツボクララン-2'-イウム · (+)-ツボクラリン · 7',12'-ジヒドロキシ-6,6'-ジメトキシ-2,2',2'-トリメチルツボクララン-2'-イウム · D-ツボクラリン · ツボクラリン · Jexin · Aids002682 · Aids-002682

識別子と物理属性
| CAS No. | 57-95-4 |
|---|---|
| 分子式 | C37H41N2O6+ |
| 平均分子量 | 609.7 g/mol |
| 単同位体質量 | 609.29646203 g/mol |
| SMILES | COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C |
| InChIKey | JFJZZMVDLULRGK-URLMMPGGSA-O |
| PubChem CID | 6000 |
| ChEMBL | CHEMBL339427 |
| ChEBI | CHEBI:9774 |
| EC No. | 886-985-5 |
| DTXSID | DTXSID0048393 |
| 現地名 | ツボクラリン |
化学・物理的性質
| XLogP | 6 |
|---|---|
| 極性表面積 | 80.6 |
| 水素結合供与体数 | 2 |
| 水素結合受容体数 | 7 |
| 回転可能結合数 | 2 |
| 重原子数 | 45 |
| 形式電荷 | 1 |
| 複雑度 | 990 |
| 医薬品 | Pharmaceuticals -> Listed in ZINC15 |
| 溶解度 | Solublity (25 °C): approx 50 mg/l waterbut supersaturated solustions are formed readily. Solubility also reported as approximately 1 g/40 ml waterapproximately 1 g/75 ml ethanol. Also soluble in methanol. Insoluble in pyridine, chloroform, benzene, acetone, ether. /Chloride, d-Form/Crystals, dec about 236 °C (effervescence)specific optical rotation: +185 deg @ 25 °C/Dto +195 °C (c=0.5 in H2O), UV max (acidified 0.005% aq soln): 280 nm (A= ~89, 1%, 1 cm). Soluble in water, dil sodium hydroxide, Sparingly sol in alcohol, in dil HCl, chlorform. Practically insoluble in benzene, ether. /Dimethyl ether/INSOL IN DIETHYL ETHER /CHLORIDE/3.23e-04 g/L |
| Decomposition | When heated to decomposition it emits toxic fumes of nitroxides. |
| 融点 | Needles from watermp: 268 °C (effervescence)specific optical rotation: -258 deg @ 20 °C (c=0.38) for the anhydrous salt /Chloride, l-Form/ |
| Optical Rotation | Hexagonal and pentagonal microplatelets from water. Can exist in the form of various hydrates. The anhydrous materl (dec 274-275 °C) takes up water in moist atm until it reaches the pentahydrate stage, dec approximately 270 °C. Specific optical rotation: +190 deg @ 22 °C/D+219 deg @ 23 °C/D (c= 0.785 in methanol). UV max (H2O): 280 nm (E=118, 1%, 1 cm). /Chloride, d-Form/ |
| Physical Description | Solid |
| Stability/Shelf Life | SENSITIVE TO LIGHT /CHLORIDE/ |
| Collision Cross Section | 236 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]235.15 Ų [M]+ [CCS Type: TW |
| Other Experimental Properties | White to light-tan crystalline alkaloidodorless. MP 270 °C with decomposition. Soluble in water and alcoholinsoluble in acetone, chloroform, and etheraqueous solution is strongly dextrorotary (specific rotation for 1% solution of anhydrous -208 to +218 degrees). /Chloride/ODORLESS, WHITE, YELLOWISH WHITE TO GRAYISH WHITE CRYSTALLINE POWDER /CHLORIDE/ODORLESS, WHITE OR PALE YELLOW CRYSTALLINE POWDER /DIMETHYL IODIDE/CRYSTALSMAX ABSORPTION: 280 NM (E= 74, 1%, 1CM)SOL IN WATER APPROX 300 MG/100 MLSLIGHTLY SOL IN DIL HYDROCHLORIC ACID, DIL SODIUM HYDROXIDEVERY SLIGHTLY SOL IN ALCPRACTICALLY INSOL IN BENZENE, ETHER, CHLOROFORMSPECIFIC OPTICAL ROTATION: +148 TO +158 DEG @ 22 °C/D (0.25%) /DIMETHYL IODIDE/SPECIFIC OPTICAL ROTATION: +190 DEG @ 22 °C/D (0.5%)+219 DEG @ 23 °C/D (METHANOL, 0.785%)DECOMP APPROX 270 °C /PENTAHYDRATE, CHLORIDE/ |
| 沸点 | 663.91°C (rough estimate) |
| 密度 | 1.1423 (rough estimate) |
| 屈折率 | 1.5300 (estimate) |
| EPAの化学物質情報 | Tubocurarine (57-95-4) |
安全性と法規制
| FDA 要件 | Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392). |
|---|---|
| 保管条件 | Store ... at controlled room temperature. ... Freezing should be avoided. /Tubocurarine chloride/ |
| 処分方法 | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
| Treatment | If the compound has been ingested, rapid gastric lavage should be performed using 5% sodium bicarbonate. For skin contact, the skin should be washed with soap and water. If the compound has entered the eyes, they should be washed with large quantities of isotonic saline or water. In serious cases, atropine and/or pralidoxime should be administered. Anti-cholinergic drugs work to counteract the effects of excess acetylcholine and reactivate AChE. Atropine can be used as an antidote in conjunction with pralidoxime or other pyridinium oximes (such as trimedoxime or obidoxime), though the use of '-oximes' has been found to be of no benefit, or possibly harmful, in at least two meta-analyses. Atropine is a muscarinic antagonist, and thus blocks the action of acetylcholine peripherally. |
| 相互作用 | EPINEPHRINE & NOREPINEPHRINE EXERT ANTICURARE EFFECT, PROBABLY BY INCR AMT OF ACH /ACETHYLCHOLINE/ RELEASED @ NERVE TERMINAL. /NEUROMUSCULAR BLOCKING AGENTS/NEUROMUSCULAR BLOCKING EFFECT OF TUBOCURARINE CAN BE ANTAGONIZED...BY... NEOSTIGMINE METHYLSULFATE OR...PYRIDOSTIGMINE...WITH ATROPINE.../&/ EDROPHONIUM CHLORIDE...HAS VERY BRIEF DURATION OF ACTION...MANY ANTIBIOTICS (EG, STREPTOMYCIN, NEOMYCIN, POLYMYXIN B, COLISTIN, KANAMYCIN, BACITRACIN, GENTAMICIN, AMIKACIN, LINCOMYCIN, CLINDAMYCIN) ENHANCE THE NEUROMUSCULAR BLOCK PRODUCED BY TUBOCURARINE ... QUINIDINE, MAGNESIUM SULFATE, AND TRIMETHAPHAN (BUT NOT SODIUM NITROPRUSSIDE) ALSO HAVE BEEN REPORTED TO POTENTIATE THE NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE.MISCELLANEOUS DRUGS THAT MAY HAVE SIGNIFICANT INTERACTIONS WITH ... COMPETITIVE ... NEUROMUSCULAR BLOCKING AGENTS INCL TRIMETHAPHAN, OPIOID ANALGESICS, PROCAINE, LIDOCAINE, QUINIDINE, PHENELZINE, PHENYTOIN, PROPANOLOL, MAGNESIUM SALTS, CORTICOSTEROIDS, DIGITALIS GLYCOSIDES, CHLOROQUINE, CATECHOLAMINES, AND DIURETICS. /NEUROMUSCULAR BLOCKING AGENTS/ |
用途
解説
ツボクラリン,非脱分極型の運動神経の神経筋接合部遮断剤の一つ。南アメリカの先住民が矢毒として用いていた数種のアルカロイドの混合物のクラーレの一成分であった。筋弛緩作用はエーテルにより増強され,ネオスチグミン,エドロフォニウムなどの抗コリンエステラーゼ剤により拮抗される。
用途
末梢性筋弛緩薬神経伝達を遮断する
使用
Neuromuscular blocking agent.